Melanoma is a type of skin cancer that develops from the cells that produce pigment in the skin. It is the most dangerous form of skin cancer and can spread quickly to other parts of the body if not caught and treated early. One of the key factors in determining the best treatment for melanoma is the presence of a Braf mutation. In this video, Melissa explains who should be tested for Braf mutation in melanoma and why it is important.
Testing for Braf mutation in melanoma is important because it can help determine the best treatment plan for a patient. Patients with the Braf V600E mutation have been found to respond well to Braf inhibitors, a type of targeted therapy that specifically targets the mutated Braf protein. This can lead to better outcomes and improved survival rates for these patients.
Who Should Be Tested for Braf Mutation?
The National Comprehensive Cancer Network (NCCN) recommends that all patients with advanced or metastatic melanoma should be tested for Braf mutation. This includes patients with stage III or IV melanoma, as well as those with recurrent or unresectable melanoma. Additionally, patients with stage II melanoma who have a high risk of recurrence should also be tested.
How is Braf Mutation Testing Done?
Braf mutation testing can be done through a variety of methods, including tissue biopsy, blood tests, and liquid biopsy. Tissue biopsy involves taking a sample of the tumor tissue and testing it for the presence of the Braf mutation. Blood tests and liquid biopsies, on the other hand, can detect the Braf mutation through a simple blood draw.
What are the Benefits of Braf Mutation Testing?
Aside from determining the best treatment plan for a patient, Braf mutation testing also has other benefits. It can help identify patients who are at a higher risk of developing melanoma, as well as those who may benefit from preventive measures such as increased sun protection. It can also help identify family members who may be at risk of inheriting the Braf mutation and developing melanoma.
Questions? Contact Melissa: https://www.aimatmelanoma.org/support-resources/talk-to-a-medical-expert/